Myriad Genetics (MYGN) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $83.3 million.
- Myriad Genetics' Accumulated Depreciation & Amortization fell 2898.55% to $83.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.3 million, marking a year-over-year decrease of 2898.55%. This contributed to the annual value of $109.6 million for FY2024, which is 859.05% down from last year.
- Latest data reveals that Myriad Genetics reported Accumulated Depreciation & Amortization of $83.3 million as of Q3 2025, which was down 2898.55% from $79.4 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Accumulated Depreciation & Amortization ranged from a high of $119.9 million in Q4 2023 and a low of $79.4 million during Q2 2025
- Its 5-year average for Accumulated Depreciation & Amortization is $106.1 million, with a median of $109.2 million in 2022.
- As far as peak fluctuations go, Myriad Genetics' Accumulated Depreciation & Amortization surged by 979.85% in 2023, and later plummeted by 3101.65% in 2025.
- Over the past 5 years, Myriad Genetics' Accumulated Depreciation & Amortization (Quarter) stood at $106.9 million in 2021, then increased by 2.15% to $109.2 million in 2022, then increased by 9.8% to $119.9 million in 2023, then dropped by 8.59% to $109.6 million in 2024, then dropped by 24.0% to $83.3 million in 2025.
- Its Accumulated Depreciation & Amortization was $83.3 million in Q3 2025, compared to $79.4 million in Q2 2025 and $83.5 million in Q1 2025.